Research-backed articles for biohacker-curious readers. No PhD required.
Metformin was the default longevity drug in the 2010s. Then Peter Attia publicly reversed on it, citing research showing it blunts the mitochondrial adaptations to exercise. An honest look at why the informed-biohacker consensus has cooled.
Sleep disruption is one of the most common complaints in perimenopause, and the mechanism is more specific than 'hormones.' Progesterone decline removes GABA-ergic calm. Estrogen fluctuation disrupts temperature regulation. Cortisol shifts change the architecture of early-morning waking.
PT-141, sold under the brand name Vyleesi, is the only FDA-approved peptide for female desire — a central-acting melanocortin receptor agonist approved in 2019 for generalized hypoactive sexual desire disorder. Here's how it works, what the trial data actually shows, and where it fits in a thoughtful women's sexual health protocol.
A research-anchored walkthrough of how estrogen, progesterone, testosterone, DHEA, SHBG, thyroid, and cortisol shift through perimenopause and menopause. No symptoms-as-prescription, just the biology.
The compounded topical formulation sometimes called 'scream cream' explained — typical ingredients, the 503A compounding framework, why the published efficacy evidence is thin, and how the FDA views the category.
A tour of the oxytocin research — Sue Carter's prairie vole pair-bonding studies, the Zak/Kosfeld intranasal trials and their replication critiques, and why functional physicians are exploring compounded oxytocin today.
The same symptoms get handled very differently by a NAMS-credentialed menopause specialist and a biohacker-optimization physician. Neither is wrong — they're different models for different patients.
There's no FDA-approved female testosterone product in the US, so most OB-GYNs won't prescribe it. Here's the history (Intrinsa, 2004), how Australia does it differently, and who in the US will write the prescription.
Combined oral contraceptives raise SHBG and lower free testosterone — the research is unambiguous on the mechanism. What's less clear is how completely it recovers after stopping. A look at the published literature.
ISSWSH, NAMS, and the Endocrine Society each publish position statements on menopausal hormone therapy, testosterone in women, and compounded bioidenticals. Where they agree, where they don't, and why it matters.
Mary Claire Haver, Sara Szal, Felice Gersh, Stacy Sims, Kelly Casperson, Rachel Rubin — plus researchers Susan Davis, Sue Carter, and JoAnn Manson. What each of them is saying, and where to actually find their work.
AgelessRx commoditized longevity protocols at entry-tier pricing. Pepvio offers premium bundled stacks with labs included and biohacker-native positioning. Here's an honest comparison to help you choose.
Midi is the leading insurance-friendly menopause platform. Pepvio serves the biohacker-optimizer framing with a three-molecule women's sexual health stack. Honest comparison of audience fit and trade-offs.
If you have a great local physician and time for labs, direct-to-pharmacy can beat Pepvio on price. Here's an honest side-by-side with real cost math so you can decide which path fits.
Rapamycin has extended median lifespan in every mammalian species tested. It's the longevity drug Bryan Johnson, Peter Attia, and an expanding cohort of physicians take personally. Here's what the research shows, how it's dosed for longevity, and who should consider it.
NAD+ is the coenzyme your cells run on, and its age-related decline is one of the clearest biomarkers of aging. Here's what the research says about injectable NAD+, how it's dosed, and why the biohacker community has moved toward it.
Testosterone is the most abundant active sex hormone in women, yet there's no FDA-approved female testosterone product. Here's what the research shows about testosterone's role in female libido, energy, and mood, and how to access it legitimately.
Female sexual health is more than one hormone. The research points toward a three-part protocol — testosterone for desire, oxytocin for bonding and arousal, and targeted arousal cream for on-demand response. Here's why they work better together.
Sermorelin and Tesamorelin are the two GHRH analog peptides that remain legally compoundable today. They do the same basic thing but differ meaningfully in potency, cost, and patient fit. Here's how to decide between them.
Peptides are naturally occurring amino acid chains that act as signaling molecules in the body. Here's what the research says about how they work and why they're gaining attention.
GLP-1 medications like semaglutide have dominated headlines, but peptides like AOD-9604 offer a different approach to fat metabolism — without the appetite suppression.
In February 2026, 14 peptides returned to FDA Category 1 status. Here's what that means for patients, providers, and legal access to peptide therapy.
Peptide therapy costs vary widely — from grey-market risks to $500+ clinic visits. Here's what you should actually expect to pay for legitimate, prescribed peptide therapy.
Peptide stacking — the practice of using two or more peptides simultaneously — is one of the most discussed topics in peptide therapy. When done under physician guidance, strategic combinations can produce synergistic effects that exceed what any single peptide achieves alone.
Athletes are increasingly turning to peptide therapy for faster recovery, better sleep, and injury rehabilitation. Here's what the research says, which peptides are most relevant, and how to navigate the legal landscape.
Peptide therapy was once limited to specialty clinics in major cities, costing hundreds per visit. Telehealth has fundamentally changed the access equation — making physician-supervised peptide protocols available to patients regardless of where they live.
After the FDA's February 2026 reclassification, 14 peptides returned to legal Category 1 status. Here's exactly where to buy them legally — and why the grey market is no longer worth the risk.
After the FDA reinstatement, dozens of telehealth platforms started offering peptide therapy. Here's how to evaluate them — and what separates the legitimate operators from the questionable ones.
Peptide therapy is having a moment, and the marketing claims have gotten ahead of the science. Here's an honest assessment of what peptides actually do — and what they don't — based on the available evidence.
Peptide therapy is generally well-tolerated, but the long-term safety data is more limited than for FDA-approved drugs. Here's what we know — and what we don't — about long-term peptide use.
Patient question we hear constantly: when will I notice results? The honest answer varies by peptide, condition, and individual — but here's a realistic timeline based on what the research and clinical experience actually show.
Peptides interact with biological pathways that overlap with many common medications. Here's what to know about combining peptide therapy with prescription drugs, supplements, and over-the-counter medications.
Yes — therapeutic peptides require a prescription in the United States. Here's exactly what that means, why the 'research chemical' loophole isn't legal, and how to actually get peptides legally in 2026.